Date: Wednesday 15th July 2020
Time: 14:00 - 15:00 (BST)
Speakers: Bruno Boulanger
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
Bruno Boulanger, PharmaLex
Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Date: Wednesday 15th July 2020
Time: 14:00 - 15:00 (BST)
Speakers: Bruno Boulanger
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
Bruno Boulanger, PharmaLex
Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Date: Wednesday 15th July 2020
Time: 14:00 - 15:00 (BST)
Speakers: Bruno Boulanger
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
Bruno Boulanger, PharmaLex
Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Date: Wednesday 15th July 2020
Time: 14:00 - 15:00 (BST)
Speakers: Bruno Boulanger
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
Bruno Boulanger, PharmaLex
Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Date: Wednesday 15th July 2020
Time: 14:00 - 15:00 (BST)
Speakers: Bruno Boulanger
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
Bruno Boulanger, PharmaLex
Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
Date: Wednesday 15th July 2020
Time: 14:00 - 15:00 (BST)
Speakers: Bruno Boulanger
You can now register for this event. Registration will close at 12:00 on 14th July 2020.
This webinar is free to attend for Members and Non-Members of PSI.
To register your place, please click here.
For 15 years the scientific literature has repeatedly underlined the important lack of reproducibility and replicability of studies in biomedical research. As a consequence, several scientific organisations (journal, scientific societies, universities, national agencies) have identified some root causes to this issue and proposed good research practices to improve the replicability of the results. The misuse of statistical concepts, from design of studies to analysis of data to decision-making is at the heart of the crisis, even if not the only cause. In this webinar we will explain the how to understand the sequences of issues and how to fix it in order to drastically improve the replicability of the results. Through example the presentation will cover concepts such as OFAT vs DoE, p-values and Bayesian statistics and Power vs Assurance as easy opportunities to improve robustness of decisions.
4 key learnings attendees will take away from this webinar:
Bruno Boulanger, PharmaLex
Bruno Boulanger has 30 years of experience in several areas of pharmaceutical research and industry including discovery, toxicology, CMC and early clinical phases. He holds various positions in Europe and in the USA while working at Eli Lilly and UCB. Bruno is also since 2000 Lecturer at the Université of Liège, in the School of Pharmacy, teaching Design of Experiments and Statistics. He is also a USP Expert, member of the Committee of Experts in Statistics since 2010. Since 2010, Bruno is the Head of Data Science within PharmaLex. Bruno has authored or co-authored more than 100 publications in applied statistics and co-edited one book in Bayesian statistics for pharmaceutical research.
